MANCHESTER, UNITED KINGDOM - (Marketwired - Nov 11, 2015) - Epistem Holdings Plc (LSE:EHP) ("Epistem" or "the Company"), the personalised medicine and biotechnology company, which has expertise evaluating treatments for gastrointestinal damage following radiation exposure, and Indiana University, with complementary experience evaluating treatments for similar bone marrow toxicity, today announced that they have received funding from…
Read more
About: admbbt
Recent Posts by admbbt
Bolder BioTechnology Receives Continued NIH Support For Preclinical Development of a Long-Acting Blood Cell Growth Factor to Treat Hematopoietic Complications of Acute Radiation Exposure
Boulder, Colorado - Jun 12, 2015 - Bolder BioTechnology, Inc. announced today that it has been awarded the third year of a Small Business Innovative Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). George (Joe) Cox, Ph.D., Company President said, “We are grateful to…
Read more
Bolder BioTechnology Receives Third Year of NIH Grant to Study Use of Blood Cell Growth Factors to Treat Acute Radiation Syndrome
Boulder, Colorado - Jun 12, 2015 - Bolder BioTechnology, Inc. announced today that it has been awarded the third year of a five year U01 Cooperative Research Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant is a joint research project between Bolder BioTechnology and…
Read more
Bolder BioTechnology Receives Continued NIH Support to Study Effects of Long-Acting Growth Factors for Treating Acute Radiation Syndrome
Boulder, Colorado - May 29, 2014 - Bolder BioTechnology, Inc. announced today that it has been awarded the second year of a five year U01 Cooperative Research Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant is a joint research project between Bolder BioTechnology and…
Read more
Recent Comments by admbbt
No comments by admbbt yet.